13th Annual Scientific Meeting of the Cardiorenal Forum

Updates and progress in cardiorenal medicine

Friday 5 October 2018
9.30 am to 5.00 pm
Royal College of
Obstetricians and
Gynaecologists, London
Past meetings awarded
6 CPD credits by the
Royal College of Physicians
Past meetings were endorsed by
The Renal Association, The
British Society for Heart Failure
and the Irish Nephrology Society
Early bird registration fees:
£100 doctors, £60 concessions
£200 commercial organisations

The Cardiorenal Forum (CRF) is an independent group formed in 2006. The key objective of the group is to highlight the important clinical overlap that exists between patients


Session 1 Diabetes and cardiorenal disease
  Chair: Paul Kalra, Consultant Cardiologist (Portsmouth Hospitals NHS Trust)
09:25 Welcome
09.30 Which drug for which patient? David Strain, Clinical Senior Lecturer (University of Exeter) and Honorary Consultant (Royal Devon and Exeter Hospital)
10.00 Understanding the pathogenesis of vascular disease in diabetes, hypertension and obesity – does it influence treatment? Anthony Heagarty, Professor of Cardiovascular Sciences (University of Manchester)
10.30 Lipid management in vascular disease – when to consider options beyond statins Dermot Neely, Consultant in Clinical Biochemistry and Metabolic Medicine (Newcastle upon Tyne Hospitals NHS Trust)
11:00 Coffee
Session 2 Cardiorenal clinical updates
  Chair: Catherine Wall, Consultant Nephrologist (Tallaght University Hospital, Dublin, Ireland)
11:40 The British Heart Valve Society Lecture
Advances in percutanous treatment of valvular disease in patients with cardiorenal disease
Phil MacCarthy, Professor of Interventional Cardiology (King’s College London) and Consultant Cardiologist (King’s College Hospital, London)
12:05 The British and Irish Hypertension Society Lecture
Blood pressure targets in patients with cardiorenal disease. What do the guidelines say?
Una Martin, Professor of Clinical Pharmacology (University of Birmingham)
12:30 British Heart Foundation Lecture
Modulating inflammation to improve cardiorenal outcomes – is clinical utility on the horizon?
Federica Marelli-Berg, British Heart Foundation Chair of Cardiovascular Immunology (William Harvey Research Institute, Barts and The London School of Medicine and Dentistry)
12:55 Lunch
Session 3 Clinical trial update
  Chairs from British Junior Cardiologists Association and Renal SpR Club
14:05 Cardiology trials reviewed (TBC)
14:30 Nephrology trial network in the UK – does it work? Philip Kalra, Professor of Renal Medicine (University of Manchester) and Consultant Nephrologist (Salford Royal NHS Foundation Trust)
Session 4 Improving patient care – examples of collaborative working between cardiologists and nephrologists
  Chair: David Lappin, Consultant Nephrologist (Galway University Hospitals, Ireland)
14:55 How to manage deteriorating renal function in patients with heart failure on RAAS blockade Charles Tomson, Consultant Nephrologist (Freeman Hospital, Newcastle upon Tyne)
15:20 Sudden cardiac death in end stage renal disease Paul Roberts, Consultant Cardiologist (University Hospital Southampton NHS Trust)
15:45 Tea break
Session 5 Interactive clinical cases in cardiorenal disease
  Chair: David Mulcahy, Consultant Cardiologist (Tallaght University Hospital, Dublin, Ireland)
16:15 Case 1. Hyperkalaemia Sunil Bhandhari, Consultant in Nephrology (East Yorkshire Hospitals NHS Trust) and Honorary Professor (Hull York Medical School)
16:35 Case 2. Anticoagulation and CKD Adrian Covic, Professor of Internal Medicine and Nephrology (University of Medicine, Gr T Popa, Iasi, Romania)
16:55 Case 3. Iron deficiency Paul WX Foley, Consultant Cardiologist (Great Western Hospital, Swindon)
17:15 Close

Would you like us to send you regular updates about the activities of the Cardiorenal Forum, including meetings?

Sign up for regular updates from the Cardiorenal Forum

You can also find out more here about our Privacy policy and Terms and conditions

Cardiorenal Forum educational podcast

Hyperkalaemia: who gets it, how frequent is it, what do I do and does it matter?

We are pleased to bring you a podcast from last year’s Cardiorenal Forum Annual Scientific Meeting, held in London on 13th October 2017. A highlight of the day’s proceedings included a lively and informative debate on hyperkalaemia – where abnormally high potassium levels are a major concern for many clinicians, particularly nephrologists and cardiologists. The fear of causing hyperkalaemia is depriving many thousands of patients of appropriate treatment.

Hyperkalaemia is often multifactorial in origin and may be seen in chronic kidney disease (CKD), acute kidney injury, heart failure, diabetes, elderly patients and those prescribed renin-angiotensin-aldosterone-system (RAAS) antagonists. This important area is often somewhat neglected by healthcare professionals. Left untreated, high potassium increases the risk of mortality in CKD and can also result in increased risk of serious cardiac arrhythmia and other acute complications. Chronically it may result in patients with heart failure having symptom and life-improving treatments withdrawn. New therapies for hyperkalaemia are now coming through...

Is hyperkalaemia more of a problem for nephrologists or for cardiologists? Watch nephrologist, David Wheeler (Royal Free Hospital, London) and cardiologist, Colin Doig (Northumbria) battle it out and answer who gets hyperkalaemia, how frequent it is and whether it matters.
Watch and enjoy the debate while learning about the condition through an entertaining combat between the kidney doctors and the heart empire, who strike back!

The Cardiorenal Forum (CRF) is an independent group formed in 2006. The key objective of the group is to highlight the important clinical overlap that exists between patients

94% of delegates said the 2017 meeting was clinically excellent or good


Royal College of Obstetricians and Gynaecologists,
27 Sussex Place, Regent’s Park,
London NW1 4RG